ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
MedImmune, AstraZeneca’s biologics drug unit, has acquired AlphaCore Pharma, an Ann Arbor, Mich.-based biotech company that is developing ACP-501, a recombinant human lecithin-cholesterol acyltransferase enzyme, as a cholesterol management agent. Several AlphaCore scientists were part of the team that discovered the Pfizer cholesterol drug Lipitor. The deal is AstraZeneca’s first acquisition since new CEO Pascal Soriot laid out a revamp plan for the company last month.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter